Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Total 13F shares
-
12,674,614
-
Share change
-
-397,687
-
Total reported value
-
$167,321,205
-
Put/Call ratio
-
86%
-
Price per share
-
$13.20
-
Number of holders
-
90
-
Value change
-
-$8,492,233
-
Number of buys
-
45
-
Number of sells
-
42
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q2 2022
As of 30 Jun 2022 BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) had 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 12,674,614 shares of stock of the company.
Largest 10 holders included FMR LLC, BlackRock Inc., Artemis Investment Management LLP, VANGUARD GROUP INC, MASSACHUSETTS FINANCIAL SERVICES CO /MA/, Rubric Capital Management LP, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, and NORTHERN TRUST CORP.
This table shows 90 institutional shareholders of the security as of 30 Jun 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.